AstraZeneca revises down efficacy rate on US Covid vaccine trial
(Sharecast News) - Pharma giant AstraZeneca revised down the efficacy rate for its US Covid-19 vaccine trial to 76% after authorities there said the company had published incomplete data in trial results.
Read more